REGN
Regeneron PharmaceuticalsPrevious close
927.89
Change
+109.12 / +13.33%
P/E (TTM) ?
19.5
Market Cap
$93.4B
1M
+22.37%
S&P 500 −0.91% over same period
Volume / Avg Volume
2.9M / 618K
4.65× average
Latest earnings analysisFY2026 Q3Reported 2026-10-06
Regeneron Q3 FY2026: revenue up 36.0% to $5.12 billion, EPS beat
Regeneron's third quarter FY2026 was a blowout on paper: revenue rose 36.0% to $5.12 billion and non-GAAP EPS of $20.07 beat the $16.56 consensus. The catch is where the money came from — $3.00 billion of collaboration revenue, mostly Sanofi's Dupixent profit share, which stepped up once the Development Balance was repaid. Read the beat as a mix of durable Dupixent economics and a one-time reset.
Read the full analysis →Revenue$5.12BYoY +36.30%
EPS (non-GAAP)$20.07Beatest. $16.56
Next-day move+0.46%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q3 Quarter ended 2026-09 | 2026-10-06 | $5.1B | Read analysis → |
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-06 | $4.3B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-08 | $3.6B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-12 | $14.3B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-06 | $3.8B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 56 of its 5-year rangeMid-range
5-year range 14.1 – 31.2 · Median 18.7
Last 4 quarters: $3.0B in buybacks + $383M in dividends, 3.66% of market cap combined
P/E (TTM)
19.5
P/B
2.7
P/S
5.4
Dividend Yield
0.45%
Earnings Reaction
Over the last 5 reports, the stock moved ±1.4% on average on the first trading day after, rising 2 times
Most recent +0.46%
Volatility & Correlation
1-year beta 0.31 · Correlation with S&P 500 0.12Low beta
Annualized volatility 33% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 6 · $6.5MNet selling $6.5M
- 10-14MURPHY ANDREW JCo-Chief Scientific OfficerSell$3.2M4,147 shares · 27 trades · Avg price 772.70
- 09-03McCourt MarionEVP CommercialSell$0.97M1,131 shares · Avg price 857.39
- 09-02Guarini KathrynDirectorSell$0.34M400 shares · Avg price 850.00
- 09-02McCourt MarionEVP CommercialSell$1.0M1,215 shares · Avg price 850.00
- 08-10Zoghbi Huda YDirectorSell$0.64M800 shares · Avg price 800.00
- 08-10Guarini KathrynDirectorSell$0.32M400 shares · Avg price 800.00
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 5.12 | +36.3% | — | 1.95 | 18.45 |
| FY2026 Q2 | 4.29 | +16.7% | — | 1.30 | 12.23 |
| FY2026 Q1 | 3.61 | +19.0% | — | 0.73 | 6.75 |
| FY2025 Q4 | 3.88 | +2.5% | — | 0.84 | 7.78 |
| FY2025 Q3 | 3.75 | +0.9% | — | 1.46 | 13.62 |
| FY2025 Q2 | 3.68 | +3.6% | — | 1.39 | 12.81 |
| FY2025 Q1 | 3.03 | −3.7% | — | 0.81 | 7.27 |
| FY2024 Q4 | 3.79 | +10.3% | — | 0.92 | 8.12 |
| FY2024 Q3 | 3.72 | +10.6% | — | 1.34 | 11.54 |
| FY2024 Q2 | 3.55 | +12.3% | — | 1.43 | 12.41 |
| FY2024 Q1 | 3.15 | −0.5% | — | 0.72 | 6.27 |
| FY2023 Q4 | 3.43 | +0.6% | — | 1.16 | 10.21 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| REGN | 19.5 | +36.3% | — | +22.37% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |